Динамика и взаимосвязь показателей состояния эндотелия и иммунного статуса у пациентов, находящихся на программном гемодиализе, на фоне лечения препаратом аторвастатин
А. Л. Барсук, А. М. Возова, Е. В. Малинок et al. · Современные технологии в медицине · 2013
Cited by 0 works.
Authors
- А. Л. Барсук
- А. М. Возова
- Е. В. Малинок
- Любовь Валерьевна Ловцова
- Окрут Ирина Евгеньевна
- Кузин Владимир Борисович
References
- Vascular Incompetence in Dialysis Patients—Protein‐Bound Uremic Toxins and Endothelial Dysfunction
- Inflammation and carnitine in hemodialysis patients
- Intraindividual Interleukin-6 Variations on the Cardiovascular Prognosis of Patients with Chronic Renal Disease
- Combined vascular effects of HMG-CoA reductase inhibitor and angiotensin receptor blocker in non-diabetic patients undergoing peritoneal dialysis
- Influence of CD4+/CD25+regulatory T cells on atherogenesis in patients with end-stage kidney disease
- A hydroxymethylglutaryl coenzyme a reductase inhibitor improves endothelial function within 7 days in patients with chronic hemodialysis
- Atorvastatin does not impair endothelial cell wound healing in an in vitro model of vascular injury.
- Simvastatin and markers of endothelial function in patients undergoing continuous ambulatory peritoneal dialysis.